Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Development of a Genetically-Engineered Allogeneic Anti-CD38 T Cell Therapy Utilizing a Novel Antigen Receptor Structure

Bei Bei Ding, PhD, John Dixon Gray, PhD, Irina Krapf, MSc, Yanliang Zhang, PhD, Nan Zhang, Qingdong Mark Deng, Angel Wei, MD, Robert D. Knight, MD, Jerome B. Zeldis, MD PhD, Gunnar F. Kaufmann, PhD, Henry Ji, PhD, Wenzhong Guo, PhD

Blood (2019) 134 (Supplement_1): 4444.

https://doi.org/10.1182/blood-2019-131586

Published: 2019

Journal Articles

Preclinical Evaluation of Human Placental-Derived Allogeneic CD19 CAR-T Cells Against B Cell Malignancies

Kathy Karasiewicz, MSc, Shuyang He, PhD, Mary Ng, MSc, Kristina Tess, Weifang Ling, PhD, Gunnar F. Kaufmann, PhD, Jerome B. Zeldis, MD PhD, Henry Ji, PhD, Robert Hariri, MD PhD, Xiaokui Zhang, PhD

Blood (2019) 134 (Supplement_1): 3222.

https://doi.org/10.1182/blood-2019-130782

Published: 2019

Journal Articles

Preclinical Characterization of an ANTI-CD38/CD3 T CELL-Redirecting Bispecific Antibody

Xiao He, PhD, Yanliang Zhang, PhD, Yun Wei Lai, MSc, Stephanie Baguley, MSc, Yan Li, PhD, Xia Cao, MSc, Ying Yan, PhD, Ken Takeshita, MD, Jerome B. Zeldis, MD PhD, Henry Ji, PhD, Gunnar F. Kaufmann, PhD

Blood (2019) 134 (Supplement_1): 4463.

https://doi.org/10.1182/blood-2019-131540

Published: 2019

Journal Articles

Development of an Allogeneic Anti-Bcma T Cell Therapy Utilizing a Novel Dimeric Antigen Receptor (DAR) Structure

Bei Bei Ding, PhD, John Dixon Gray, PhD, Nan Zhang, Yanliang Zhang, PhD, Xia Cao, MSc, Irina Krapf, MSc, Qingdong Mark Deng, Angel Wei, MD, Jerome B. Zeldis, MD PhD, Robert D. Knight, MD, Gunnar F. Kaufmann, PhD, Henry Ji, PhD, Wenzhong Guo, PhD

Blood (2019) 134 (Supplement_1): 1942.

https://doi.org/10.1182/blood-2019-131892

Published: 2019

Journal Articles

Development of CD38 CAR Engineered Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (PNK-CAR38) As Allogeneic Cancer Immunotherapy

Srinivas Somanchi, PhD, Xuan Guo, PhD, Shuyang He, PhD, Rohit Mathur, PhD, Andrea Difiglia, BS, Hemlata Rana, MS, Weifang Ling, PhD, James Edinger, PhD, Gunnar F. Kaufmann, PhD, Jerome B. Zeldis, MD PhD, Henry Ji, PhD, Robert Hariri, MD PhD, Xiaokui Zhang, PhD

Blood (2019) 134 (Supplement_1): 2070.

https://doi.org/10.1182/blood-2019-129539

Published: 2019

Journal Articles

Pomalidomide Induces Expansion of Activated and Central Memory CD4+ and CD8+ T Cells in Vivo in Patients with and without HIV Infection

Mark N. Polizzotto, MBBS, FRACP, FRCPA, Irini Sereti, MD, Thomas S. Uldrick, MD MS, Kathleen M. Wyvill, RN, Stig M. R. Jensen, PhD, Amrit Singh, BSc, Stephen B. Kovacs, BSc, Karen O. Aleman, RN, Vickie Marshall, PhD, Denise Whitby, PhD, Frank Maldarelli, MD PhD, Seth M. Steinberg, PhD, Jerome B. Zeldis, MD PhD, Robert Yarchoan, MD

Blood (2014) 124 (21): 4128.

https://doi.org/10.1182/blood.V124.21.4128.4128

Published: 2014

Journal Articles

Lenalidomide and Dexamethasone in the Treatment of AL Amyloidosis: Final Results of A Phase II Trial

Divya Nair, MD, Vaishali Sanchorawala, MD, Anthony C Shelton, RN, Salli A Fennessey, Kathleen T Finn, ANP, Martha Skinner, MD, Jerome B. Zeldis, MD, PhD, David C Seldin, MD, PhD

Blood (2012) 120 (21): 4084.

https://doi.org/10.1182/blood.V120.21.4084.4084

Published: 2012

Journal Articles

Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis

Umit Tapan, David C. Seldin, Kathleen T. Finn, Salli Fennessey, Anthony Shelton, Jerome B. Zeldis, Vaishali Sanchorawala

Blood (2010) 116 (23): 5071–5072.

https://doi.org/10.1182/blood-2010-09-305136

Published: 2010

Journal Articles

Increases In B-Type Natriuretic Peptide (BNP) During Treatment with Lenalidomide In AL Amyloidosis

Umit Tapan, MD, David C Seldin, MD, PhD, Kathleen T Finn, ANP, Salli Fennessey, CRA, Anthony C Shelton, RN, Jerome B. Zeldis, MD, PhD, Vaishali Sanchorawala, MD

Blood (2010) 116 (21): 3021.

https://doi.org/10.1182/blood.V116.21.3021.3021

Published: 2010

Journal Articles

Lenalidomide Treatment In Patients with AL Amyloidosis Associated End-Stage Renal Disease and Dialysis

Vaishali Sanchorawala, MD, Kathleen T Finn, ANP, Salli Fennessey, CRA, Anthony C Shelton, RN, Jerome B. Zeldis, MD, PhD, David C Seldin, MD, PhD

Blood (2010) 116 (21): 3022.

https://doi.org/10.1182/blood.V116.21.3022.3022

Published: 2010

Journal Articles

Mature Results of MM011: A Phase I/II Trial of Lenalidomide, Liposomal Doxorubicin, Dexamethasone, and Vincristine, Followed by Lenalidomide Maintenance (DVd-R) for Relapsed or Refractory Multiple Myeloma

Aleksandr Lazaryan, MD, MPH, PhD, Rachid Baz, MD, Mohamad A Hussein, Jr, MD, Paul Elson, ScD, Beth Faiman, CNP, Becky Habecker, Mary Ann Karam, RN, Janice Reed, RN, Kimberly Hamilton, RN, Kellie Bruening, Gordan Srkalovic, MD, PhD, Steven Andresen, DO, Matt Kalaycio, MD, John William Sweetenham, MD, FRCP, Ronald Sobecks, MD, Robert Dean, MD, Robert Knight, MD, Jerome B. Zeldis, MD, PhD, Frederic J. Reu, MD

Blood (2010) 116 (21): 1967.

https://doi.org/10.1182/blood.V116.21.1967.1967

Published: 2010

Journal Articles

Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis

Vaishali Sanchorawala, Kathleen T. Finn, Salli Fennessey, Anthony Shelton, Gheorghe Doros, Jerome B. Zeldis, David C. Seldin

Blood (2010) 116 (11): 1990–1991.

https://doi.org/10.1182/blood-2010-07-295485

Published: 2010

Journal Articles

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

Luhua Wang, MD, Luis Fayad, MD, Fredrick B. Hagemeister, MD, Sattva Neelapu, MD, Felipe Samaniego, MD, Peter McLaughlin, MD, Barry Samuels, MD, Qing Yi, MD, PhD, Barbara Pro, MD, Michelle Fanale, M.D., Jatin Shah, MD, Anas Younes, MD, Neda Bell, Robert Knight, MD, Jerome B. Zeldis, MD, PhD, Fernando Cabanillas, MD, Larry Kwak, MD, PHD, Jorge Romaguera, MD

Blood (2009) 114 (22): 2719.

https://doi.org/10.1182/blood.V114.22.2719.2719

Published: 2009

Journal Articles

Overview of Venous Thromboembolism (VTE) in Nearly 100,000 Patients Treated with Revlimid® (lenalidomide).

Lilia Weiss, MD, Kamal Shah, MD, Wai Yiu, PharmD, John Freeman, MSc., BSc., LLB, DipClinSci., Robert Knight, MD, Jerome B. Zeldis, MD

Blood (2009) 114 (22): 2881.

https://doi.org/10.1182/blood.V114.22.2881.2881

Published: 2009

Journal Articles

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

Michael Wang, Meletios A. Dimopoulos, Christine Chen, M. Teresa Cibeira, Michel Attal, Andrew Spencer, S. Vincent Rajkumar, Zhinuan Yu, Marta Olesnyckyj, Jerome B. Zeldis, Robert D. Knight, Donna M. Weber

Blood (2008) 112 (12): 4445–4451.

https://doi.org/10.1182/blood-2008-02-141614

Published: 2008

Journal Articles

Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma

Michael Wang, MD, Liang Zhang, PhD, Luis Fayad, MD, Fredrick Hagemeister, MD, Sattva Neelapu, MD, Felipe Samaniego, M.D., Barbara Pro, MD, Anas Younes, MD, Scott Miller, Robert D. Knight, MD, Jerome B. Zeldis, MD, Qing Yi, MD, PhD, Jorge Romaguera, MD

Blood (2008) 112 (11): 3058.

https://doi.org/10.1182/blood.V112.11.3058.3058

Published: 2008

Journal Articles

Oral Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Multiple Myeloma Patients: Kinetics of Neutropenia/Thrombocytopenia and Time to Event Results

Antonio Palumbo, MD, Patrizia Falco, MD, Francesca Gay, MD, Paolo Corradini, MD, Claudia Crippa, MD, Francesco Di Raimondo, MD, Antonietta Falcone, MD, Nicola Giuliani, MD, Pellegrino Musto, MD, Fortunato Morabito, MD, Letizia Canepa, MD, Alessandro Gozzetti, MD, Simona Caltagirone, PhD, Jerome B. Zeldis, MD, Robert D. Knight, MD, Mario Boccadoro, MD, Maria Teresa Petrucci, MD

Blood (2008) 112 (11): 2768.

https://doi.org/10.1182/blood.V112.11.2768.2768

Published: 2008

Journal Articles

Confirmation of the Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory Diffuse Large-B-Cell Lymphoma: Results of An International Study (NHL-003)

Myron S. Czuczman, MD, Julie M. Vose, MD, Pier Luigi Zinzani, MD, Craig B. Reeder, MD, Rena Buckstein, MD, FRCPC, Corinne Haioun, Reda Bouabdallah, MD, Jonathan Polikoff, MD, Pingshan Guo, Annette Ervin-Haynes, Dennis Pietronigro, Jerome B. Zeldis, MD, Thomas E. Witzig

Blood (2008) 112 (11): 268.

https://doi.org/10.1182/blood.V112.11.268.268

Published: 2008

Journal Articles

Safety and Efficacy Outcomes with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma Were Not Significantly Different for the Treatment of Patients with or without High-Risk Disease or Elderly Status

Asher Chanan-Khan, MD, Meletios A Dimopoulos, MD, Donna M. Weber, Andrew Spencer, Michel Attal, MD, Andrew Belch, MD, Alessandro Corso, Tommy Fu, Jerome B. Zeldis, MD, Marta Olesnyckyj, Robert D. Knight, MD, Sagar Lonial, MD

Blood (2008) 112 (11): 3701.

https://doi.org/10.1182/blood.V112.11.3701.3701

Published: 2008

Journal Articles

Longer Duration of Treatment and Maintenance of Best Response with Lenalidomide and Dexamethasone Prolongs Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma

Jesús F San Miguel, Meletios A Dimopoulos, MD, Edward A. Stadtmauer, MD, S. Vincent Rajkumar, MD, David Siegel, Marie-Laure Bravo, Marta Olesnyckyj, Robert D. Knight, MD, Jerome B. Zeldis, MD, Jean-Luc Harousseau, Donna M. Weber

Blood (2008) 112 (11): 3702.

https://doi.org/10.1182/blood.V112.11.3702.3702

Published: 2008

NARROW

Development of a Genetically-Engineered Allogeneic Anti-CD38 T Cell Therapy Utilizing a Novel Antigen Receptor Structure

Preclinical Evaluation of Human Placental-Derived Allogeneic CD19 CAR-T Cells Against B Cell Malignancies

Preclinical Characterization of an ANTI-CD38/CD3 T CELL-Redirecting Bispecific Antibody

Development of an Allogeneic Anti-Bcma T Cell Therapy Utilizing a Novel Dimeric Antigen Receptor (DAR) Structure

Development of CD38 CAR Engineered Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (PNK-CAR38) As Allogeneic Cancer Immunotherapy

Pomalidomide Induces Expansion of Activated and Central Memory CD4+ and CD8+ T Cells in Vivo in Patients with and without HIV Infection

Lenalidomide and Dexamethasone in the Treatment of AL Amyloidosis: Final Results of A Phase II Trial

Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis

Increases In B-Type Natriuretic Peptide (BNP) During Treatment with Lenalidomide In AL Amyloidosis

Lenalidomide Treatment In Patients with AL Amyloidosis Associated End-Stage Renal Disease and Dialysis

Mature Results of MM011: A Phase I/II Trial of Lenalidomide, Liposomal Doxorubicin, Dexamethasone, and Vincristine, Followed by Lenalidomide Maintenance (DVd-R) for Relapsed or Refractory Multiple Myeloma

Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

Overview of Venous Thromboembolism (VTE) in Nearly 100,000 Patients Treated with Revlimid® (lenalidomide).

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma

Oral Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Multiple Myeloma Patients: Kinetics of Neutropenia/Thrombocytopenia and Time to Event Results

Confirmation of the Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory Diffuse Large-B-Cell Lymphoma: Results of An International Study (NHL-003)

Safety and Efficacy Outcomes with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma Were Not Significantly Different for the Treatment of Patients with or without High-Risk Disease or Elderly Status

Longer Duration of Treatment and Maintenance of Best Response with Lenalidomide and Dexamethasone Prolongs Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only